A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China

N/AActive Not RecruitingNCT06512337

Bristol-Myers Squibb153 enrolled

Overview

The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.

Study Type

OBSERVATIONAL

Enrollment

153

Conditions

Plaque Psoriasis

Interventions

DeucravacitinibDRUG

As per product label

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participant aged 18 years or older * Physician-reported (dermatologist) diagnosis of moderate plaque psoriasis with Body Surface Area ≥ 3% and \< 10% * Participant newly initiated deucravacitinib according to the label * Provided written informed consent to participate in the study Exclusion Criteria: * Participating in or planning to participate in an interventional clinical trial * Concomitant use of other systemic treatments for psoriasis at baseline * Prior treatment of deucravacitinib

Locations (5)

Local Institution - 0001

Guangzhou, Guangdong, China

Local Institution - 0002

Handan, Hebei, China

Local Institution - 0005

Dalian, Liaoning, China

Local Institution - 0004

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

Number of participants achieving Static Physician's Global Assessment (sPGA) 0/1 score

Time frame: Week 16

Participant psoriasis Body Surface Area (BSA) involvement

Time frame: Week 16

Number of participants achieving absolute Psoriasis Area and Severity Index (PASI) score ≤ 3

Time frame: Week 16

Secondary Outcomes

Number of participants achieving Psoriasis Area and Severity Index (PASI) 75 response and PASI 90 response

Time frame: Baseline and Weeks 4, 12, 24, 36, and 52

Number of participants achieving absolute Psoriasis Area and Severity Index (PASI) score ≤1, ≤2, ≤3, and ≤5

Time frame: Baseline and Weeks 4, 12, 24, 36, and 52

Participants change in Participant Absolute Psoriasis Area and Severity Index (PASI) score from baseline

Time frame: Weeks 4, 12, 16, 24, 36, and 52

Number of participants achieving psoriasis Body Surface Area (BSA) involvement of ≤1% and ≤3%

Time frame: Baseline and Weeks 4, 12, 16, 24, 36, and 52

Change in Body Surface Area (BSA) involvement from baseline to follow-up

Time frame: Weeks 4, 12, 24, 36, and 52

Static Physician's Global Assessment (sPGA) 0/1 response at follow-up

Time frame: Weeks 4, 12, 24, 36, and 52

Participants change in Static Physician's Global Assessment (sPGA) score from baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.